{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059338","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.072395+00:00","generated_at":"2026-06-02T05:59:07.005157+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Theravance Biopharma shareholders elect three Class I directors, ratify EY, approve say-on-pay","bullets":["Elected Eran Broshy, James Kelly, Laurie Smaldone Alsup as Class I directors for three-year terms; votes for each exceeded 35 million.","Ratified Ernst & Young as independent auditor for FY 2024 with 39,257,982 for, 228,078 against.","Non-binding advisory resolution on named executive officer compensation passed with 35,205,714 for, 332,345 against.","Total shares voted at annual meeting: 39,493,689 (81.3% of outstanding)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059338","json":"https://secwatch.observer/filing/0001104659-24-059338.json","markdown":"https://secwatch.observer/filing/0001104659-24-059338.md","text":"https://secwatch.observer/filing/0001104659-24-059338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/0001104659-24-059338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/tm2413991d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:59:07.005157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a8285349d7a0d271dc0dd6438c6b297c1f52fef","claim":"Theravance Biopharma, Inc. shareholders approved Election of Class I directors: Eran Broshy, James Kelly, Laurie Smaldone Alsup at the 2024-05-08 meeting.","evidence_excerpt":"Proposal One – Based on the following results of voting, the nominees listed below were elected Class I directors to serve as members of the Board until the Company’s Annual General Meeting held in 2026 and until their successors are duly elected and qualified: Nominees For Against Abstain Broker Non- Votes Eran Broshy 35,316,310 223,797 635 3,952,947 James Kelly 35,265,676 274,631 435 3,952,947 Laurie Smaldone Alsup 35,290,841 240,365 9,536 3,952,947","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/0001104659-24-059338-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"9654bfe900e330c1b7f6fbe6e747179262e01fa2","claim":"Theravance Biopharma, Inc. shareholders approved Non-binding advisory resolution regarding compensation of named executive officers at the 2024-05-08 meeting.","evidence_excerpt":"Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non- Votes Number of Shares Voted 35,205,714 332,345 2,683 3,952,947","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/0001104659-24-059338-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"f63969468a4f9be3cf158b9261cf12400dfb4df3","claim":"Theravance Biopharma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-08 meeting.","evidence_excerpt":"Proposal Two – Based on the following results of voting, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified: For Against Abstain Broker Non- Votes Number of Shares Voted 39,257,982 228,078 7,629 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/0001104659-24-059338-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}